Immunotherapy - Checkpoint Inhibitor, Targeted Immunotherapy Drugs
Offered By: Mary Greeley Medical Center via YouTube
Course Description
Overview
Syllabus
Intro
Case Presentation
Immune Checkpoints --Biology
PD1 Inhibitor for Melanoma
PD1 Trials in Melanoma
Combination of CTLA4 and PD1 blockade in Melanoma: Checkmate 067 Trial
Adjuvant Checkpoint Inhibitor Treatment --Melanoma Adjuvant Ipilimumab was studied in comparison to placebo in treatment of patients who had undergone complete resection of stage lIl Melanoma at a dose of 10 mg.kg every 3 weeks X 4 followed by every 3 months X 3 years. - At 5.3 years follow-up the recurrence free survival was 40.8% in Ipilimumab group compared to 30.3% in placebo
Adjuvant PD1 Inhibitors for Stage III Melanoma
Checkpoint Inhibitors in Advanced NSCLC
Predictors of Response
(PACIFIC Trial) Checkpoint Inhibitor as Adjuvant Therapy after Chemo- Radiotherapy for Stage III NSCLC
Management of Toxicity
Taught by
Mary Greeley Medical Center
Related Courses
VaccinesUniversity of Pennsylvania via Coursera Healthcare Innovation and Entrepreneurship
Duke University via Coursera Clinical Problem Solving
University of California, San Francisco via Coursera Contraception: Choices, Culture and Consequences
University of California, San Francisco via Coursera Vaccine Trials: Methods and Best Practices
Johns Hopkins University via Coursera